Want to see CAH full AI Analyst Report?
CAH Stock Chart & Stats
$228.03
$2.05(0.91%)
At close: 4:00 PM EDT
$228.03
$2.05(0.91%)
Day’s Range― - ―
52-Week Range$145.87 - $258.30
Previous CloseN/A
Volume1.47M
Average Volume (3M)2.27M
Market Cap
$54.62B
Enterprise Value$61.08K
Total Cash (Recent Filing)$4.86B
Total Debt (Recent Filing)$9.95B
Price to Earnings (P/E)31.4
Beta0.30
Next Earnings
Oct 30, 2026EPS Estimate
2.94Next Dividend Ex-DateN/A
Dividend Yield0.9%
Share Statistics
EPS (TTM)7.27
Shares Outstanding232,575,730
10 Day Avg. Volume2,156,172
30 Day Avg. Volume2,265,102
Financial Highlights & Ratios
PEG Ratio2.68
Price to Book (P/B)-19.45
Price to Sales (P/S)0.22
P/FCF Ratio12.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$270.00Price Target Upside18.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)12.53
Revenue Forecast (FY)$265.58B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Profit GrowthCardinal’s scale across pharmaceutical distribution, specialty care and other healthcare businesses is translating into broad-based growth. Sustained volume, mix and operating improvements can support durable earnings expansion over the next several quarters.
Robust Cash GenerationStrong cash conversion gives Cardinal resources to fund operations, capital investment, debt obligations and shareholder returns. Although working capital can create volatility, the sizable recurring cash base improves strategic flexibility in a low-margin distribution model.
Positive Outlook And Diversified GrowthManagement expects continued earnings growth above its 12%–14% long-term target, supported by Pharma, Specialty and faster-growing businesses such as Nuclear/PET and Theranostics. This diversification reduces reliance on a single distribution category.
Bears Say
Negative Equity And Rising DebtThe persistent negative equity position and higher debt weaken balance-sheet resilience and reduce financial flexibility. In a structurally low-margin business, elevated leverage can constrain investment capacity and increase exposure to financing or operating setbacks.
Structurally Low MarginsCardinal’s high-volume distribution model produces substantial revenue but limited profit per dollar of sales. Small changes in pricing, purchasing terms, product mix, labor or logistics costs can therefore have an outsized and lasting effect on earnings quality.
Regulatory And Cost PressuresRegulatory changes affecting reimbursement and purchasing economics may pressure pharmaceutical volumes and margins, while fuel and resin costs can raise expenses. The one-time tariff refund also makes reported profit growth less representative of normalized performance.
Cardinal Health News
CAH FAQ
What was Cardinal Health’s price range in the past 12 months?
Cardinal Health lowest stock price was $145.87 and its highest was $258.30 in the past 12 months.
What is Cardinal Health’s market cap?
Cardinal Health’s market cap is $54.62B.
When is Cardinal Health’s upcoming earnings report date?
Cardinal Health’s upcoming earnings report date is Oct 30, 2026 which is in 69 days.
How were Cardinal Health’s earnings last quarter?
Cardinal Health released its earnings results on Aug 11, 2026. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.49.
Is Cardinal Health overvalued?
According to Wall Street analysts Cardinal Health’s price is currently Undervalued.
Does Cardinal Health pay dividends?
Cardinal Health pays a Quarterly dividend of $0.516 which represents an annual dividend yield of 0.9%. See more information on Cardinal Health dividends here
What is Cardinal Health’s EPS estimate?
Cardinal Health’s EPS estimate is 2.94.
How many shares outstanding does Cardinal Health have?
Cardinal Health has 232,575,730 shares outstanding.
What happened to Cardinal Health’s price movement after its last earnings report?
Cardinal Health reported an EPS of $2.91 in its last earnings report, beating expectations of $2.42. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Cardinal Health?
Currently, no hedge funds are holding shares in CAH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardinal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$270.00 (18.41% Upside)
$270.00 (18.41% Upside)
Blogger Sentiment
Bullish
CAH Sentiment 93%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 587.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $59.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.47%
12-Months-Change
Fundamentals
Return on Equity
0.90%
Trailing 12-Months
Asset Growth
7.86%
Trailing 12-Months
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
CAH Company Deck
CAH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, broad-based fiscal '26 performance across revenue, profit, EPS (Q4 EPS +40% YoY) and cash flow ($5B adjusted FCF), with clear operational momentum in Pharma, Specialty and Other growth businesses and disciplined capital return (share buybacks and increased repurchase authorization). Key risks highlighted include reliance on a nonrecurring $100M IEEPA tariff refund that materially boosted GMPD profitability and $0.31 of Q4 EPS, input cost pressures (fuel and commodity resins), regulatory headwinds (IRA/340B impacts ~500 bps mentioned), and expected near-term cadence softness (Q1 FY27 headwind). Overall, positives around scale, cash generation, segment momentum and reconfirmed long‑term targets materially outweigh the transitory and manageable challenges discussed.View all CAH earnings summariesCAH Revenue Breakdown
91.94% Pharmaceutical and Specialty Solutions
5.68% Global Medical Products and Distribution
2.42% Other
-0.04% Corporate

CAH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$270.00
▲(18.41% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
0.25% Insiders
22.86% Mutual Funds
11.78% Other Institutional Investors
33.47% Public Companies and Individual Investors










